With the development of new immunotherapies in the pipeline, cancer immunotherapy based on immune checkpoint blockade has achieved unprecedented success and moved rapidly into combination therapies centered on the use of anti-PD-1(Emerging immunotherapy for HCC 2022). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.